AbbVie Inc (ABBV)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
Volatility-scaled: the stop sits about 2× the average daily range (ATR 2.5% of price) below the price, with a 2:1 reward-to-risk target. Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+26% over the past year+3
- 52-week positionPressing 52-week highs+30
- QualityRevenue growing 11% y/y+5
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is **none** — these headlines are dividend/valuation commentary and peer comparisons rather than a discrete company event like earnings, a product readout, or M&A. Continuation likelihood of any near-term directional move is **low (roughly 30–40%)**, since sentiment-driven coverage without a hard catalyst tends to fade rather than sustain a trend. Informational only — not financial advice.
- How Retirees Can Turn $175,000 Into Passive Income With These 4 Dividend StocksYahoo · 2026-11-15
- Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?Yahoo · 2026-11-14
- AbbVie (ABBV) Stock Looks Below Fair Value After Strong Cash Flow GrowthYahoo · 2026-11-14
- Could You Have Held Glaukos Stock Through Its Falls?Yahoo · 2026-11-14
- What Is The Market Seeing In Eli Lilly Stock?Yahoo · 2026-11-14
Any AI summary is an interpretation of public news, not advice or a price target.